NsG33 - Meteorin

NsGene has over the years discovered several novel neurotrophic proteins with therapeutic potential. One of these proteins, named NsG33 or Meteorin in the literature, has advanced through several in vitro and in vivo studies. NsG33 belongs to a new two-member family of neurotrophic factors also including NsG34 (Cometin). This new family is well conserved across species and NsGene has obtained strong patent positions on both proteins.

In vitro studies using recombinant protein have demonstrated that NsG33 promotes extensive neurite outgrowth of dissociated dorsal root ganglion cultures, especially the nociceptive sensory neurons, pointing at a therapeutic use in the treatment of neuropathy and associated neuropathic pain. Indeed, NsGene has demonstrated a profound therapeutic effect of repeated subcutaneous injections of NsG33 in well established in vivo models of neuropathic pain. Data suggest a neurotrophic modification of the underlying neuropathy rather than symptomatic pain relief and importantly no side effects of the systemic administration of NsG33 have been observed.

In addition to the effects of NsG33 in the peripheral nervous system, NsGene has demonstrated that NsG33 strongly protects striatal neurons against neurotoxicity in the QA in vivo model of Huntington’s disease.

For a list of scientific literature on Meteorin, click here.